Macrogenics Inc (MGNX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Macrogenics reported revenue of $149.5M, down 0.3% from $150.0M the year before. Net income was -$74.6M (a -49.9% net margin), or -$1.18 per diluted share. Gross margin was 100.0% and operating margin was -48.7%. Operating activities generated -$81.0M of cash, leaving -$83.0M of free cash flow. At fiscal year end, Macrogenics held $256.8M in total assets against $201.3M in total liabilities, including $57.2M of cash and equivalents.
Open the full interactive Macrogenics financials → Quarterly statements, key ratios, valuation history and price charts.
Macrogenics Key Stats
| Share Price | $3.42 |
|---|---|
| Market Cap | $217.5M |
| Revenue YoY Growth | -0.3% |
| 52-Week Range | $1.33 – $4.86 |
| Shares Outstanding | 63.6 million (basic, 2026 Q2) |
Macrogenics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $104.9M | $77.4M | $151.9M | $58.7M | $150.0M | $149.5M |
| Cost of Goods Sold | — | $2.7M | $3.4M | $619,000 | $847,000 | $0 |
| Gross Profit | — | $74.8M | $148.6M | $58.1M | $149.1M | $149.5M |
| Operating Income | -$131.1M | -$202.8M | -$121.4M | -$168.2M | -$110.6M | -$72.8M |
| Pre-Tax Income | -$129.7M | -$202.1M | -$119.8M | -$9.1M | -$66.0M | -$75.3M |
| Income Tax | $0 | $0 | $0 | $0 | $944,000 | -$672,000 |
| Net Income | -$129.7M | -$202.1M | -$119.8M | -$9.1M | -$67.0M | -$74.6M |
| Diluted EPS | -$2.47 | -$3.37 | -$1.95 | -$0.15 | -$1.07 | -$1.18 |
Macrogenics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $72.8M | $41.2M | $20.8M | $32.8M |
| Net Income | $16.8M | -$14.2M | -$36.8M | $19.5M |
| Diluted EPS | $0.27 | -$0.22 | -$0.58 | $0.31 |
Macrogenics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $181.1M | $123.5M | $108.9M | $101.0M | $182.8M | $57.2M |
| Current Assets | $312.6M | $279.6M | $222.2M | $251.3M | $217.5M | $219.9M |
| Total Assets | $378.7M | $335.2M | $280.5M | $298.4M | $261.7M | $256.8M |
| Current Liabilities | $50.7M | $74.6M | $48.6M | $56.1M | $55.5M | $43.1M |
| Total Liabilities | $82.9M | $95.6M | $138.5M | $145.8M | $145.6M | $201.3M |
| Shareholders' Equity | $295.9M | $239.6M | $142.0M | $152.6M | $116.1M | $55.6M |
Macrogenics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$111.9M | -$143.8M | -$87.0M | -$78.2M | -$68.4M | -$81.0M |
| Cash From Investing | -$7.8M | -$36.6M | $70.7M | -$80.1M | $149.3M | -$114.1M |
| Cash From Financing | $174.3M | $122.8M | $1.7M | $150.4M | $960,000 | $69.5M |
| Free Cash Flow | -$117.8M | -$150.0M | -$90.6M | -$80.0M | -$72.1M | -$83.0M |
Figures from Macrogenics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Macrogenics financials page for every line item.
Macrogenics Company Profile
| Ticker | MGNX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Rockville, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001125345 |
Frequently Asked Questions
What was Macrogenics' revenue in fiscal 2025?
Macrogenics (MGNX) reported revenue of $149.5M for fiscal 2025.
What is Macrogenics' annual revenue history?
Macrogenics' annual revenue by fiscal year: 2020: $104.9M; 2021: $77.4M; 2022: $151.9M; 2023: $58.7M; 2024: $150.0M; 2025: $149.5M.
What was Macrogenics' net income in fiscal 2025?
Macrogenics reported net income of -$74.6M for fiscal 2025.
What was Macrogenics' earnings per share (EPS) in fiscal 2025?
Macrogenics' diluted EPS was -$1.18 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Macrogenics generate in fiscal 2025?
Macrogenics generated -$83.0M of free cash flow in fiscal 2025.
What was Macrogenics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Macrogenics reported revenue of $32.8M.
How many shares of Macrogenics are outstanding?
Macrogenics reported a weighted average of 63.6 million basic shares outstanding in 2026 Q2.
What is Macrogenics' market cap?
Based on its latest closing price, Macrogenics (MGNX) has a market capitalization of about $217.5M.
When does Macrogenics' fiscal year end?
Macrogenics' fiscal year end, as registered with the SEC, is December 31.
Where is Macrogenics headquartered?
Macrogenics lists its business address in Rockville, Maryland in its SEC filings.